What is the appropriate way to administer Totilac (3% sodium‑lactate solution) to an adult ESRD patient on chronic hemodialysis who is actively bleeding?

Administration of Totilac in ESRD Patients on Hemodialysis with Active Bleeding

I cannot provide specific guidance on administering "Totilac" (3% sodium-lactate solution) to ESRD patients on hemodialysis with active bleeding, as the provided evidence does not contain information about this specific product or its use in this clinical scenario.

Critical Gap in Evidence

The evidence provided does not include FDA labeling, guidelines, or research specifically addressing Totilac (3% sodium-lactate solution) administration in ESRD patients with bleeding complications. The drug label evidence provided 1 pertains to ketorolac tromethamine (Toradol), which is an NSAID—not a lactate-based solution—and is actually contraindicated in patients with active bleeding given its antiplatelet effects.

What the Evidence Does Address

Lactate Use in Hemodialysis (General Context)

• Lactate can be used as a dialysate base in hemodialysis solutions, either alone or combined with acetate, and is generally well-tolerated without hypotension 2
• Both D- and L-lactate isomers are metabolized in maintenance hemodialysis patients 2
• Hemodialysis reduces lactate levels by approximately 27% overall, with greater reductions (37-62%) in patients with elevated baseline lactate 3

Bleeding Management During Hemodialysis

For ESRD patients at high risk of bleeding undergoing hemodialysis, anticoagulation strategies must be modified 4, 5, 6:

• Heparin-free dialysis with saline flushes is an option for patients with active bleeding 4, 5
• Alternative approaches include minimal heparinization, regional citrate anticoagulation, or heparin-bound membranes 4
• The bleeding risk with standard anticoagulation must be carefully balanced against circuit thrombosis risk 6

Clinical Recommendation

Without specific product information, FDA labeling, or clinical guidelines for Totilac in this population, I cannot recommend its use. Before administering any sodium-lactate solution to an ESRD patient on hemodialysis with active bleeding, you must:

• Obtain the complete FDA-approved prescribing information for the specific product
• Consult nephrology and the dialysis team regarding compatibility with the patient's dialysis prescription
• Verify there are no contraindications related to the bleeding disorder
• Ensure appropriate monitoring protocols are in place

The priority in this clinical scenario is managing the active bleeding and ensuring safe hemodialysis delivery, which may require heparin-free dialysis protocols 4, 5.